Interestingly, while DGAT inhibitors are close to being available on the market in the context of obesity and diabetes [57], trabedersen, a specific antisense oligonucleotide directed against the TGF-β2 gene, is already available and currently used in the clinic [58,59,60]. The gene discussed is DGAT1; the disease is obesity due to melanocortin 4 receptor deficiency.